Company Profile

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE646.4010.15 (+1.6 % )
PREV CLOSE (Rs.) 636.25
OPEN PRICE (Rs.) 643.90
BID PRICE (QTY) 646.50 (169 )
OFFER PRICE (QTY) 647.20 (91 )
VOLUME 7204
TODAY'S LOW / HIGH (Rs.)637.00 651.00
52 WK LOW / HIGH (Rs.)483.6 711.55
NSE646.05 10.4 (+1.64 % )
PREV CLOSE(Rs.) 635.65
OPEN PRICE (Rs.) 639.90
BID PRICE (QTY) 646.10 (46 )
OFFER PRICE (QTY) 646.50 (10 )
VOLUME 206596
TODAY'S LOW / HIGH(Rs.) 636.30 647.85
52 WK LOW / HIGH (Rs.)493.5 711.9

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.31
TTM EPS (Rs.) 52.84
P/E Ratio 12.22
Book Value (Rs.) 414.85
Face Value (Rs.) 1
MCap (Rs. in Mn) 182210.09
Price/Earning (TTM) 11.34
Price/Sales (TTM) 2.89
Price/Book (MRQ) 1.56
PAT Margin (%) 15.77
ROCE (%) 11.02
Incorporation Year : 1977

Management Info :

Glenn Saldanha - Chairman Glenn Saldanha - Managing Director

Registered Office :

Address : B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone :

Registrar's Details : Karvy Fintech Pvt Ltd.-(Karvy Computuershare Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
15Mar03-15-2019$Glenmark’s arm gets USFDA’s final approval for Clindamycin, Benzoyl Peroxide Gel Glenmark’s arm gets USFDAâ

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clindamycin and Benzoyl Peroxide Gel, 1%/5%, a generic version of BenzaClin Gel, 1%/5%, of Valeant Bermuda. According to IQVIA sales data for the 12 month period ending January 2019, the BenzaClin Gel, 1%/5% market achieved annual sales of approximately $99.4 million.

The company’s current portfolio consists of 151 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceutic..
15Mar03-15-2019$Glenmark Pharmaceuticals informs about media release Glenmark Pharmaceuticals inf

Glenmark Pharmaceuticals has informed about submission of media release which is self explanatory.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about submission of media..
15Mar03-15-2019$Glenmark shines as its arm gets USFDA’s final approval for Clindamycin, Benzoyl Peroxide Gel Glenmark shines as its arm g

Glenmark Pharmaceuticals is currently trading at Rs. 641.90, up by 11.50 points or 1.82% from its previous closing of Rs. 630.40 on the BSE.

The scrip opened at Rs. 635.00 and has touched a high and low of Rs. 647.50 and Rs. 634.80 respectively. So far 10952 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 711.55 on 10-Sep-2018 and a 52 week low of Rs. 483.60 on 30-May-2018.

Last one week high and low of the scrip stood at Rs. 645.75 and Rs. 603.00 respectively. The current market cap of the company is Rs. 18101.09 crore.

The promoters holding in the company stood at 46.54%, while Institutions and Non-Institutions held 39.20% and 14.26% respectively.

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Clindamycin and Benzoyl Peroxide Gel, 1%/5%, a generic version of BenzaClin Gel, 1%/5%, of Valeant Bermuda. According to IQVIA sales data for the 12 month period ending January 2019, the BenzaClin Gel, 1%/5% market achieved annual sales of approximately $99.4 million.

The company’s current portfolio consists of 151 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these, the company continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals is currently trading at Rs. 641.90, up..
06Mar03-06-2019$Glenmark Pharmaceuticals informs about media release Glenmark Pharmaceuticals inf

Glenmark Pharmaceuticals has informed about submission of media release titled ‘Glenmark Pharmaceuticals Announces Appointment of Alessandro Riva as CEO of its New Innovation Company’, which is self explanatory.

The above information is a part of company’s filings submitted to BSE.

Glenmark Pharmaceuticals has informed about submission of media..
05Mar03-05-2019$Glenmark presents new subtype analysis of GBR 830 in Washington Glenmark presents new subtyp

Glenmark Pharmaceuticals has presented a new post hoc analysis of data from a Phase 2a, proof-of-concept study of GBR 830 at the American Academy of Dermatology (AAD) Annual Meeting in Washington, DC.

GBR 830 is an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD). The Phase 2a study was conducted to investigate the safety of GBR 830, evaluate its effects on AD biomarkers, and generate the first clinical evidence of its biological activity. The study was not powered for statistical differences between GBR 830 and placebo.

The new, post hoc analysis of the Phase 2a study was conducted to evaluate the activity of GBR 830 in patients with intrinsic and extrinsic AD subtypes, and for subjects with elevated IgE levels at baseline. The analyses demonstrated that baseline clinical scores (EASI, SCORAD, IGA) were consistent regardless of a patient’s AD subtype or whether they had elevated IgE. Reductions in SCORAD clinical scores were observed throughout the treatment period.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharmaceuticals has presented a new post hoc analysis..
Financials More
Rs. in Millions
QTR Dec 18 ANNUAL 18
Net Profit1958.7110143.47
Gross Profit 1838.28 12188.25
Operating Profit 2647.1415279.27
Net Sales 16320.3664318.84
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Piramal Enterprises (BSE)
 2615.25 (1.60%)
M.Cap ( in Cr)
48196.31
Valiant Organics (BSE)
 1575.00 (1.94%)
M.Cap ( in Cr)
923.64
Sanofi India (BSE)
 5590.00 (0.53%)
M.Cap ( in Cr)
12874.12
Torrent Pharma (BSE)
 1881.00 (0.94%)
M.Cap ( in Cr)
31853.54
Alkem Laboratories (BSE)
 1723.75 (0.56%)
M.Cap ( in Cr)
20610.02
Shareholding Pattern More
PROMOTERS 46.54 %
MUTUAL FUNDS/UTI 4.02 %
FI/BANKS/INSURANCE 2.72 %
NON-INSTITUTION 14.26 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes

Open A

New Account

Name
Email
Mobile Number
City
Select Products You Are Interested